Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer

摘要: Ovarian cancer is known as the silent killer for being asymptomatic until late stages. Current first-line treatment consists of debulking surgery followed by i.v. chemotherapeutics administered intermittently, which leads to insufficient drug concentrations at tumor sites, accelerated proliferation rates, and resistance, resulting in an overall median survival only 2 4 years. For these reasons, more effective strategies must be developed. We have investigated a localized, continuous chemotherapy approach models human murine ovarian cancers using antineoplastic agent docetaxel. show here that docetaxel therapy considerably efficacious than intermittent therapy, greater decrease burden ascites fluid accumulation. Immunohistochemical analyses abrogates cell angiogenesis microenvironment, leading death therapy. Overall, our results therapeutic advantages over cancer.